http://biz.yahoo.com/prnews/080214/aqth013.html?.v=39 7:31AM Dendreon presents data correlating the cumulative potency of PROVENGE to overall survival; correlation appeared to be independent of other important baseline prognostic factors (DNDN) 5.55 : Co presents data demonstrating the correlation of a measure of the cumulative potency of PROVENGE (sipuleucel-T), an investigational active cellular immunotherapy for hormone-refractory prostate cancer, with overall survival. This is the first time that an association between higher potency of an active immune therapy and increased patient survival has been reported. The correlation appeared to be independent of other important baseline prognostic factors. Results showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE or higher cumulative CD54 upregulation values. The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors.